Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors

Gene Therapy

Volumn 17, Issue 5, 2010, Pages 616-625

  Han, Y ^a   Chang, Q A ^a   Virag, T ^a   West, N C ^a   George, D ^a   Castro, M G ^b   Bohn, M C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Parkinson's disease; Regulated gene expression; RtTA; TTA; Viral vectors

Indexed keywords

AMINO ACID DECARBOXYLASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE TRANSFERASE; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PURIFICATION; RAT; REGULATORY MECHANISM; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BASAL GANGLIA; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNITY, HUMORAL; MALE; PARKINSON DISEASE; RATS; RATS, INBRED F344; RECOMBINANT FUSION PROTEINS; RESPONSE ELEMENTS; TETRACYCLINE; TRANS-ACTIVATORS; TRANSGENES;

ADENOVIRIDAE; PRIMATES; RATTUS;

EID: 77952425513     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.6     Document Type: Article

References (49)

1. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008; 70: 1980-1983.
2. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14: 564-570.
3. Sanchez-Pernaute R, Harvey-White J, Cunningham J, Bank-iewicz KS. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther 2001; 4: 324-330.
4. Choi-Lundberg DL, Lin Q, Schallert T, Crippens D, Davidson BL, Chang YN et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 1998; 154: 261-275.
5. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-773.
6. Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838-841.
7. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line- derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997; 94: 8818-8823.
8. Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, Forsayeth J. Clinically relevant effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged Rhesus monkeys. Hum Gene Ther 2009; 20: 497-510.
9. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-424.
10. Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 1997; 777: 153-160.
11. During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 1998; 5: 820-827.
12. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer J. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5: 42-49.
13. Feng X, Eide FF, Jiang H, Reder AT. Adeno-associated viral vector-mediated ApoE expression in Alzheimer's disease mice: low CNS immune response, long-term expression, and astrocyte specificity. Front Biosci 2004; 9: 1540-1546.
14. Paterna JC, Moccetti T, Mura A, Feldon J, Bueler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Therapy 2000; 7: 1304-1311.
15. Andersen JK, Frim DM, Isacson O, Breakefield XO. Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cell Mol Neurobiol 1993; 13: 503-515.
16. Ye X, Rivera VM, Zoltick P, Cerasoli Jr F, Schnell MA, Gao G et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283: 88-91.
17. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T et al. A humanized system for pharmacologic control of gene expression. Nat Med 1996; 2: 1028-1032.
18. Serguera C, Bohl D, Rolland E, Prevost P, Heard JM. Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells. Hum Gene Ther 1999; 10: 375-383.
19. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
20. Ralph GS, Bienemann A, Harding TC, Hopton M, Henley J, Uney JB. Targeting of tetracycline-regulatable transgene expression specifically to neuronal and glial cell populations using adenoviral vectors. Neuroreport 2000; 11: 2051-2055.
21. Lee YB, Cosgrave AS, Glover CP, Bienemann A, Heywood D, Hobson RJ et al. Increased utility in the CNS of a powerful neuron-specific tetracycline- regulatable adenoviral system developed using a post-transcriptional enhancer. J Gene Med 2005; 7: 576-583.
22. Blesch A, Conner J, Pfeifer A, Gasmi M, Ramirez A, Britton W et al. Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons. Mol Ther 2005; 11: 916-925.
23. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Horsten S, Schmidt T et al. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 2008; 28: 2471-2484.
24. Liu B, Wang S, Brenner M, Paton JF, Kasparov S. Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain. J Gene Med 2008; 10: 583-592.
25. Xiong W, Goverdhana S, Sciascia SA, Candolfi M, Zirger JM, Barcia C et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 2006; 80: 27-37.
26. Xiong W, Candolfi M, Kroeger KM, Puntel M, Mondkar S, Larocque D et al. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther 2008; 16: 343-351.
27. Curtin JF, Candolfi M, Puntel M, Xiong W, Muhammad AK, Kroeger K et al. Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators. Methods Mol Biol 2008; 434: 239-266.
28. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
29. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Joussemet B, Bujard H et al. Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther 2004; 9: 410-418.
30. Favre D, Blouin V, Provost N, Spisek R, Porrot F, Bohl D et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 2002; 76: 11605-11611.
31. Latta-Mahieu M, Rolland M, Caillet C, Wang M, Kennel P, Mahfouz I et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611-1620.
32. Ginhoux F, Turbant S, Gross DA, Poupiot J, Marais T, Lone Y et al. HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system. Mol Ther 2004; 10: 279-289.
33. Corey L, Reeves WC, Holmes KK. Cellular immune response in genital herpes simplex virus infection. N Engl J Med 1978; 299: 986-991.
34. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003; 3: 879-889.
35. Peden CS, Manfredsson FP, Reimsnider SK, Poirier AE, Burger C, Muzyczka N et al. Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Mol Ther 2009; 17: 524-537.
36. Cunningham J, Pivirotto P, Bringas J, Suzuki B, Vijay S, Sanftner L et al. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 2008; 16: 1267-1275.
37. Hadaczek P, Forsayeth J, Mirek H, Munson K, Bringas J, Pivirotto P et al. Transduction of non-human primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 2009; 3: 225-237.
38. Stieger K, Mendes-Madeira A, Meur GL, Weber M, Deschamps JY, Nivard D et al. Oral administration of doxycycline allows tight control of transgene expression: a key step towards gene therapy of retinal diseases. Gene Therapy 2007; 14: 1668-1673.
39. Stieger K, Le Meur G, Lasne F, Weber M, Deschamps JY, Nivard D et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 2006; 13: 967-975.
40. Folliot S, Briot D, Conrath H, Provost N, Cherel Y, Moullier P et al. Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector. J Gene Med 2003; 5: 493-501.
41. Jiang L, Rampalli S, George D, Press C, Bremer EG, O'Gorman MR et al. Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR. Gene Therapy 2004; 11: 1057-1067.
42. Rendahl KG, Leff SE, Otten GR, Spratt SK, Bohl D, Van Roey M et al. Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biotechnol 1998; 16: 757-761.
43. Bohl D, Salvetti A, Moullier P, Heard JM. Control of erythro-poietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 1998; 92: 1512-1517.
44. Bohl D, Bosch A, Cardona A, Salvetti A, Heard JM. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood 2000; 95: 2793-2798.
45. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996; 219: 220-227.
46. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Therapy 2003; 10: 955-963.
47. Ebert AD, Chen F, He X, Cryns VL, Bohn MC. A tetracycline-regu-lated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp Neurol 2005; 191 (Suppl 1): S80-S94.
48. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
49. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.